AR081401A1 - Compuestos de espiro isoxazolina como antagonistas de sstr5 - Google Patents

Compuestos de espiro isoxazolina como antagonistas de sstr5

Info

Publication number
AR081401A1
AR081401A1 ARP110101689A ARP110101689A AR081401A1 AR 081401 A1 AR081401 A1 AR 081401A1 AR P110101689 A ARP110101689 A AR P110101689A AR P110101689 A ARP110101689 A AR P110101689A AR 081401 A1 AR081401 A1 AR 081401A1
Authority
AR
Argentina
Prior art keywords
heterocycle
substituted
halogen
alkyl
cycloalkyl
Prior art date
Application number
ARP110101689A
Other languages
English (en)
Spanish (es)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR081401A1 publication Critical patent/AR081401A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP110101689A 2010-05-18 2011-05-17 Compuestos de espiro isoxazolina como antagonistas de sstr5 AR081401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34568310P 2010-05-18 2010-05-18

Publications (1)

Publication Number Publication Date
AR081401A1 true AR081401A1 (es) 2012-08-29

Family

ID=44991994

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101689A AR081401A1 (es) 2010-05-18 2011-05-17 Compuestos de espiro isoxazolina como antagonistas de sstr5

Country Status (8)

Country Link
US (1) US20130040978A1 (OSRAM)
EP (1) EP2571356A4 (OSRAM)
JP (1) JP2013529210A (OSRAM)
AR (1) AR081401A1 (OSRAM)
AU (1) AU2011256444B2 (OSRAM)
CA (1) CA2799414A1 (OSRAM)
TW (1) TW201200524A (OSRAM)
WO (1) WO2011146324A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2605658B1 (en) 2010-08-18 2016-03-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
JP2015525223A (ja) 2012-06-14 2015-09-03 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 動物有害生物を駆除するための置換３−ピリジルチアゾール化合物および誘導体を使用する有害生物防除方法
FR3000064A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes
EP2970331B1 (en) 2013-03-14 2017-05-17 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists
CN105814064A (zh) * 2013-12-17 2016-07-27 默沙东公司 作为胆固醇酯转运蛋白的抑制剂的稠合双环异噁唑啉类
CN104945416B (zh) * 2014-03-24 2017-11-17 中国科学院上海药物研究所 一类螺异噁唑啉衍生物、其制备方法及医药用途
JPWO2015146561A1 (ja) * 2014-03-26 2017-04-13 住友精化株式会社 臭化芳香族エステル化合物の製造方法
US10011572B2 (en) 2014-07-29 2018-07-03 Merck Sharp & Dohme Corp. Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
TW201712012A (zh) 2015-06-16 2017-04-01 美國禮來大藥廠 ２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物
US10538490B2 (en) 2016-10-25 2020-01-21 Boehringer Ingelheim International Gmbh Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
CN110177773B (zh) 2017-01-26 2023-08-25 勃林格殷格翰国际有限公司 苄基氨基吡啶基环丙烷羧酸、其药物组合物及其用途
CN110248929B (zh) 2017-01-26 2023-05-12 勃林格殷格翰国际有限公司 苄基氨基吡嗪基环丙烷甲酸、其药物组合物和用途
WO2018170284A1 (en) 2017-03-16 2018-09-20 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
WO2019157458A1 (en) 2018-02-12 2019-08-15 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
JP7431813B2 (ja) 2018-09-18 2024-02-15 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレーターとその使用
TWI841768B (zh) 2019-08-14 2024-05-11 美商克林提克斯醫藥股份有限公司 非肽生長抑制素(somatostatin)5型受體激動劑及其用途
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
AR120652A1 (es) * 2019-12-03 2022-03-09 Kallyope Inc Antagonistas de sstr5
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
CN117043149A (zh) 2021-02-17 2023-11-10 克林提克斯医药股份有限公司 促生长素抑制素调节剂的结晶形式
CN115215787A (zh) * 2021-04-19 2022-10-21 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其用途
CN116354961B (zh) * 2021-12-27 2025-07-25 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其药物组合物及用途
CN114230552B (zh) * 2021-12-29 2023-11-03 江苏广域化学有限公司 三氟甲氧基二苯并噻吩、其制备方法及相关中间体的制备方法
US20240254106A1 (en) 2022-12-13 2024-08-01 Crinetics Pharmaceuticals, Inc. Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof
CN115819186B (zh) * 2023-02-14 2023-05-16 广东银珠医药科技有限公司 一种3,5-二氯苯甲醇的新型制备方法
TWI890384B (zh) 2023-03-27 2025-07-11 日商思可海雅藥品股份有限公司 Sstr5拮抗劑之用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939418A (en) * 1995-12-21 1999-08-17 The Dupont Merck Pharmaceutical Company Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors
AU6780398A (en) * 1997-03-28 1998-10-22 Du Pont Merck Pharmaceutical Company, The Heterocyclic integrin inhibitor prodrugs
DE102005044813A1 (de) * 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
JP4855468B2 (ja) * 2005-09-02 2012-01-18 エフ．ホフマン−ラ ロシュ アーゲー ベンゾオキサゾール、オキサゾロピリジン、ベンゾチアゾール及びチアゾロピリジン誘導体
CA2626628A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type iv inhibitors

Also Published As

Publication number Publication date
CA2799414A1 (en) 2011-11-24
US20130040978A1 (en) 2013-02-14
EP2571356A4 (en) 2013-11-20
EP2571356A1 (en) 2013-03-27
WO2011146324A1 (en) 2011-11-24
AU2011256444A1 (en) 2012-10-18
TW201200524A (en) 2012-01-01
JP2013529210A (ja) 2013-07-18
AU2011256444B2 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
AR081401A1 (es) Compuestos de espiro isoxazolina como antagonistas de sstr5
CL2014003277A1 (es) Compuestos derivados heterociclicos sustituidos por carboxamida o sulfonamida, como moduladores para el receptor nuclear huerfano rorgama; composicion farmaceutica que los comprende, util para el tratamiento de artritis reumatoide, lupus eritematoso, psoriasis, esclerosis multiple, diabetes tipo 1, colitis ulcerosa, enfermedad pulmonar obstructiva cronica, entre otras.
CL2014000288A1 (es) Compuestos tipo anilina; proceso para preparar dicho compuesto; uso del compuesto para controlar plagas de invertebrados; forma cristalina de un compuesto.
AR069862A1 (es) Inhibidores de pi3 quinasa
PE20141996A1 (es) Compuestos con actividad nematicida
ES2869172T3 (es) Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro
CO6852096A2 (es) Métodos plaguicidasque utilizan compuestos de 3-piridil tiazol sustituidos y derivados para combatir las plagas de animales i
AR095823A1 (es) Compuesto de ciclopropanamina y uso del mismo
DOP2012000263A (es) Compuestos quimicos
AR088668A1 (es) Moleculas pequeñas que contienen boro
PE20141691A1 (es) Compuestos con actividad nematicida
AR098912A1 (es) Inhibidores de syk
AR091285A1 (es) Inhibidores de bromodominio y sus usos
AR105668A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CL2013003602A1 (es) Compuestos derivados de benzoimidazol (indol) de analogos de espirocarbamato o sus sales como antagonistas de trpv4; composicion farmaceutica que los comprende, util para el tratamiento de aterosclerosis, trastornos relacionados con edema intestinal, trastornos pulmonares, enfermedad cardiovascular, disfuncion renal, osteoartritis, entre otras.
BR112014004235A2 (pt) derivados de isoxazolina como compostos inseticidas
PE20161368A1 (es) Inhibidores de diacilglicerol aciltranferasa 2
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
PE20142282A1 (es) Nuevos derivados de aril-quinolina
AR102217A1 (es) Derivados de benzotiofenilo sustituidos como agonistas de gpr40 para el tratamiento de la diabetes tipo ii
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
AR111199A1 (es) Compuesto aromático agonista de gpr40
AR097866A1 (es) Derivados de 4-azaindol
PE20190414A1 (es) Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat)
AR105549A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal